Actinium shares are trading lower after the FDA determined that its Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B.
Portfolio Pulse from Benzinga Newsdesk
Actinium shares are trading lower after the FDA determined that its Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B.
August 05, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Actinium Pharmaceuticals (ATNM) shares are trading lower after the FDA determined that its Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B.
The FDA's determination that the Phase 3 SIERRA trial is not adequate for a BLA filing is a significant setback for Actinium Pharmaceuticals. This news is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100